Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Aim (1)
- Side effects associated with chemotherapy
- Lipid-based nanotechnologies: a clinical reality (1)
- Lipid-based nanotechnologies: a clinical reality (2)
- Caelyx®
- Aim (2)
- Thermosensitive pegylated liposomes
- Thermodox delivers more doxorubicin into tumors
- survival benefit in the HEAT subgroup analysis
- HEAT study phase III by Celsion
- OPTIMA study (NCT02112656)
- Aim (3)
- Ligand-mediated target lipid-based nanotechnology
- Targeting the tumor microenvironment
- The different roles of nucleolin
- pH-sensitive liposomes (PEGASEMP™)
- Suppression of tumor invasion to adjacent tissues
- Relevance
- PEGASEMP™ as treatment for mesothelioma
- Aim (4)
- Abraxane™
- Abraxane & metastatic breast cancer
- Abraxane is used to treat other cancers
- Paclitaxel and immunotherapy
- Aim (5)
- Thank you!
- Acknowledgments
Topics Covered
- The need for delivery system in oncology
- Lipid-based nanotechnologies: a clinical reality
- Improving biodistribution and pharmacokinetics and safety
- Improving therapeutic outcome upon increasing drug release at target organ
- Targeting tumor microenvironment at two different cell levels
- Improving formulation
Talk Citation
Moreira, J.N. (2019, October 31). Need for drug delivery systems 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/BUPE7855.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. João Nuno Moreira has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Need for drug delivery systems 2
Published on October 31, 2019
28 min
Other Talks in the Series: Drug Delivery
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name is João Nuno Moreira,
I work at the Center for Neuroscience and Cell Biology and at
the Faculty of Pharmacy at University of Coimbra in Portugal.
0:12
The goal of my talk today will be to answer this simple question,
why do we need drug delivery systems specifically within the field of oncology?
So I'm going through several examples that will help us out
to answer in a very simple manner to this very simple question.
0:31
We have a summary of the main side effects that
oncological patients go through when they are treated with conventional chemotherapy.
Now, the problem of conventional chemotherapy upon
intravenous injection results from the fact that
these drugs have a very high volume of distribution,
meaning that these drugs once injected in the blood,
they are rapidly redistributed throughout the body and so they tend to accumulate in
healthy organs where there are a number of
different cells that they have a very high rate of proliferation.
For example in the bone marrow,
GI tract or hair follicles.
It is the accumulation and these chaotic biodistribution of
these drugs that leads to a number of side effects that are
summarized on this slide like for example
mouth sores and this can be something in a very high extent that might lead
to the inability of the patient to actually be
fat in a regular manner or alopecia, so hair falling.
So this means that under these circumstances,
oncologists have two choices;
either they stopped treatment or they must give
the patient suboptimal doses and often these ends up in treatment failure.